Reserve access to the ONCO-PDO test
Patient-derived organoid testing that brings ex vivo drug sensitivity data to your oncology practice. Register today and our team will contact you to discuss how we can support your patients.
Ex vivo
drug profiling
Why ONCO-PDO
Bridging the gap between tumor biology and treatment decisions through patient-derived organoid models.
Patient-Derived Organoids
PDO models grown from your patients' tumor tissue for personalized drug response testing.
Rapid Turnaround
Actionable ex vivo drug sensitivity results delivered in a clinically relevant timeframe.
Clinical-Grade Quality
Standardized, reproducible workflows validated for oncology research and translational use.
Actionable Insights
Data-driven reports to support treatment decisions and therapy selection for your patients.
How Our Technology Works
Watch this short video to understand the ONCO-PDO workflow and how patient-derived organoids bring actionable insights to your practice.
104+ Drugs Available for Testing
Select up to 8 single agents or combinations to screen against your patient's organoid model. Drugs marked with * incur additional fees.
* Additional fees apply for drug testing involving these agents. Prices upon request.
All Solid Tumor Types Supported
ONCO-PDO can be applied to all solid tumor types — 55+ cancers across 8 body systems.
Breast & Gynecologic
Gastrointestinal
Thoracic & Respiratory
Genitourinary
Head & Neck
Skin & Soft Tissue
Endocrine & Nervous System
Other Solid Tumors
How It Works
Three simple steps to get started.
Register
Complete the registration form with your details.
We Contact You
Our team reaches out to discuss your needs and patients.
Start Testing
Reserve access and begin the ONCO-PDO workflow.
Reserve Your Access
Fill out the form below and our team will contact you to discuss ONCO-PDO test access and the cancer types you're interested in for your patients.